Family Care Center's Novel TMS Protocol Achieves Strong Results in Treatment-Resistant Depression — Family Care Center, LLC

Event summary

Family Care Center's sequential bilateral TMS protocol achieved a ~70% response rate and 42% remission in adolescents/young adults with treatment-resistant depression.
86% of suicidal patients saw reduced ideation, with 57% reporting no suicidality post-treatment.
Protocol adds only 3 minutes to standard TMS sessions, making it practical for clinical adoption.
Study published June 29, 2026 in Transcranial Magnetic Stimulation journal.

The big picture

This study addresses a critical gap in mental health treatment for adolescents and young adults with depression, where standard antidepressants often fail. The protocol's ability to reduce suicidality—a challenge many treatments struggle with—positions it as a potential game-changer. Family Care Center is expanding its leadership in TMS therapy innovation while growing rapidly across five U.S. states.

What we're watching

Clinical Adoption Pace: Whether the sequential bilateral TMS protocol will gain rapid adoption among mental health providers given its demonstrated efficacy and minimal workflow disruption.
Regulatory Expansion: How quickly the FDA may expand approval for this protocol to broader patient populations beyond treatment-resistant depression in adolescents/young adults.
Competitive Differentiation: Whether Family Care Center can maintain a competitive edge as other providers potentially adopt or replicate this bilateral stimulation approach.